Clinical trialNCT04245397RecruitingPhase 1Interventional

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

SponsorSyntrix Biosystems, Inc.Enrollment151Myelodysplastic Syndromes

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

David A Sallman, MD
Moffitt Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic
Jacksonville, Florida, United States
Hemant S Murthy, MD
Recruiting
University of Miami
Miami, Florida, United States
Namrata S Chandhok, MD
Recruiting
Adventhealth Medical Group & Bone Marrow Transplant at Orlando
Orlando, Florida, United States
Arlene Gayle, M.D.
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
David A Sallman, MD
Recruiting
Emory University
Atlanta, Georgia, United States
Anthony M Hunter, MD
Recruiting
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
Amy E DeZern, MD, MHS
Recruiting
Montefiore Medical Center
The Bronx, New York, United States
Mendel Goldfinger, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Decitabine →SX-682

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Jun 2020
Primary completion: 31 Mar 2028
Completion: 31 Mar 2029
Last update posted: 23 Dec 2025
Registered enrollment: 151
Registry id: NCT04245397

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.